164 related articles for article (PubMed ID: 9160304)
21. Ovarian serous surface papillary borderline tumors form sea anemone-like masses.
Tanaka YO; Okada S; Satoh T; Matsumoto K; Oki A; Nishida M; Yoshikawa H; Saida T; Minami M
J Magn Reson Imaging; 2011 Mar; 33(3):633-40. PubMed ID: 21287653
[TBL] [Abstract][Full Text] [Related]
22. Isolation and preliminary characterization of an ovarian carcinoma cell line from a patient with familial ovarian cancer.
Buller RE; Niemann T; Connor JP; Squatrito RC; Skilling JS; Anderson B
Gynecol Oncol; 1995 Jan; 56(1):39-44. PubMed ID: 7821846
[TBL] [Abstract][Full Text] [Related]
23. Cystic nephroma and mixed epithelial and stromal tumor of kidney: a detailed clinicopathologic analysis of 34 cases and proposal for renal epithelial and stromal tumor (REST) as a unifying term.
Turbiner J; Amin MB; Humphrey PA; Srigley JR; De Leval L; Radhakrishnan A; Oliva E
Am J Surg Pathol; 2007 Apr; 31(4):489-500. PubMed ID: 17414095
[TBL] [Abstract][Full Text] [Related]
24. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
25. Ependymomas of the central nervous system and adult extra-axial ependymomas are morphologically and immunohistochemically distinct--a comparative study with assessment of ovarian carcinomas for expression of glial fibrillary acidic protein.
Idowu MO; Rosenblum MK; Wei XJ; Edgar MA; Soslow RA
Am J Surg Pathol; 2008 May; 32(5):710-8. PubMed ID: 18360284
[TBL] [Abstract][Full Text] [Related]
26. Immunophenotype of human ovarian malignancies (cystadenocarcinomata and mixed müllerian tumor) established in SCID mice.
Schumacher U; Adam E; Dietl J; Horny HP
Exp Mol Pathol; 1997 Apr; 64(2):103-13. PubMed ID: 9316588
[TBL] [Abstract][Full Text] [Related]
27. [Apropos of 1 case of paratesticular papillary serous cystadenocarcinoma].
Dupré F; Zachar D; Choquenet C; Clément N; Mainguene C; Vieillefond A
Ann Pathol; 2001 Feb; 21(1):63-6. PubMed ID: 11223563
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention.
Rodríguez-Burford C; Barnes MN; Berry W; Partridge EE; Grizzle WE
Gynecol Oncol; 2001 Jun; 81(3):373-9. PubMed ID: 11371125
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological significance of DEK overexpression in serous ovarian tumors.
Han S; Xuan Y; Liu S; Zhang M; Jin D; Jin R; Lin Z
Pathol Int; 2009 Jul; 59(7):443-7. PubMed ID: 19563407
[TBL] [Abstract][Full Text] [Related]
31. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors.
Choi YL; Kim SH; Shin YK; Hong YC; Lee SJ; Kang SY; Ahn G
Gynecol Oncol; 2005 May; 97(2):379-86. PubMed ID: 15863133
[TBL] [Abstract][Full Text] [Related]
32. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms.
Yakirevich E; Sabo E; Lavie O; Mazareb S; Spagnoli GC; Resnick MB
Clin Cancer Res; 2003 Dec; 9(17):6453-60. PubMed ID: 14695148
[TBL] [Abstract][Full Text] [Related]
33. Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation.
Gilcrease MZ; Delgado R; Albores-Saavedra J
Arch Pathol Lab Med; 1998 Oct; 122(10):907-11. PubMed ID: 9786352
[TBL] [Abstract][Full Text] [Related]
34. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
35. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
36. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor-beta expression in human testicular germ cell tumors.
Pais V; Leav I; Lau KM; Jiang Z; Ho SM
Clin Cancer Res; 2003 Oct; 9(12):4475-82. PubMed ID: 14555521
[TBL] [Abstract][Full Text] [Related]
38. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
Goldstein NS; Uzieblo A
Am J Clin Pathol; 2002 Apr; 117(4):541-5. PubMed ID: 11939727
[TBL] [Abstract][Full Text] [Related]
39. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors.
Cathro HP; Stoler MH
Hum Pathol; 2005 Feb; 36(2):195-201. PubMed ID: 15754297
[TBL] [Abstract][Full Text] [Related]
40. An immunohistochemical and morphological analysis of post-chemotherapy ovarian carcinoma.
Miller K; Price JH; Dobbs SP; McClelland RH; Kennedy K; McCluggage WG
J Clin Pathol; 2008 May; 61(5):652-7. PubMed ID: 18006668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
